PMID- 21429719
OWN - NLM
STAT- MEDLINE
DCOM- 20130419
LR  - 20171116
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
VI  - 22
IP  - 11
DP  - 2012 Nov
TI  - Comparison of the effects of n-3 long chain polyunsaturated fatty acids and 
      fenofibrate on markers of inflammation and vascular function, and on the serum 
      lipoprotein profile in overweight and obese subjects.
PG  - 966-73
LID - S0939-4753(11)00004-4 [pii]
LID - 10.1016/j.numecd.2010.12.010 [doi]
AB  - BACKGROUND AND AIMS: To compare the effects of n-3 long chain polyunsaturated 
      fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation 
      and vascular function, and on the serum lipoprotein profile in overweight and 
      obese subjects. METHODS AND RESULTS: Twenty overweight and obese subjects 
      participated in a randomized, double-blind, placebo-controlled intervention trial 
      and received 3.7 g/d n-3 fatty acids (providing 1.7 g/d EPA and 1.2 g/d DHA), 200 
      mg fenofibrate or placebo treatment for 6 weeks separated by a 2 weeks wash-out 
      period. Fish oil and fenofibrate treatment reduced triglyceride (-0.61 +/- 0.81 
      mmol/L, P < 0.001, and -0.34 +/- 0.85 mmol/L, P = 0.048, respectively) and 
      increased HDL cholesterol concentrations (0.13 +/- 0.21 mmol/L, P = 0.013, and 0.10 
      +/- 0.18 mmol/L, P = 0.076), as reflected by a decrease of large very VLDL 
      particles and increases of large HDL particles and medium size HDL particles. 
      Fish oil increased serum LDL cholesterol concentrations (0.34 +/- 0.59 mmol/L, P = 
      0.013). Fenofibrate reduced concentrations of soluble endothelial selectin 
      (sE-selectin) (-4.1 +/- 7.5 ng/mL, P = 0.032), but increased those of macrophage 
      chemoattractant protein 1 (MCP1) (28 +/- 55 ng/mL, P = 0.034). Fish oil had no 
      effects on these markers. CONCLUSION: Although n-3 LCPUFA and fenofibrate can 
      both activate PPARalpha, they have differential effects on cardiovascular risk 
      markers. In overweight and obese subjects fenofibrate (200 mg/d) or n-3 LCPUFA 
      (3.7 g/d) treatment for 6 weeks did not improve markers for low-grade systemic 
      inflammation, while fenofibrate had more profound effects on plasma lipids and 
      markers for vascular activity compared to fish oil. Registration number clinical 
      trials EudraCT 2006-005743-28.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Bragt, M C E
AU  - Bragt MC
AD  - Nutrigenomics Consortium, Top Institute Food and Nutrition, PO BOX 557, 6700 AN 
      Wageningen, The Netherlands. m.bragt@maastrichtuniversity.nl
FAU - Mensink, R P
AU  - Mensink RP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110322
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (E-Selectin)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fish Oils)
RN  - 0 (PPAR alpha)
RN  - 0 (Triglycerides)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/*analysis/blood
MH  - Cardiovascular Diseases/prevention & control
MH  - Chemokine CCL2/blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Docosahexaenoic Acids/administration & dosage
MH  - Double-Blind Method
MH  - E-Selectin/blood
MH  - Fatty Acids, Omega-3/*pharmacology
MH  - Female
MH  - Fenofibrate/*pharmacology
MH  - Fish Oils/administration & dosage
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Male
MH  - Metabolic Syndrome/prevention & control
MH  - Middle Aged
MH  - Obesity/*blood
MH  - Overweight/*blood
MH  - PPAR alpha/blood
MH  - Risk Factors
MH  - Triglycerides/blood
EDAT- 2011/03/25 06:00
MHDA- 2013/04/23 06:00
CRDT- 2011/03/25 06:00
PHST- 2010/06/03 00:00 [received]
PHST- 2010/11/17 00:00 [revised]
PHST- 2010/12/27 00:00 [accepted]
PHST- 2011/03/25 06:00 [entrez]
PHST- 2011/03/25 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - S0939-4753(11)00004-4 [pii]
AID - 10.1016/j.numecd.2010.12.010 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):966-73. doi: 
      10.1016/j.numecd.2010.12.010. Epub 2011 Mar 22.